• If you are wondering whether Stryker at around US$306.76 is priced high, low, or somewhere in between, this article walks through the key clues in the current valuation.
• The stock has risen about 7.5% over the past week, yet it remains down about 10.6% over the past month, 11.9% year to date, and 21.4% over the past year. This may change how you think about its risk and return profile.
• Recent coverage around Stryker has focused on how the stock's longer term returns of 10.7% over 3 years and 26.4% over 5 years compare with the weaker 1-year performance. This mix of time frames is shaping how investors interpret whether recent share price moves reflect temporary sentiment or a more persistent shift.
• Right now, Stryker scores 2 out of 6 on Simply Wall St's valuation checks, as shown in its valuation scorecard. The rest of this article walks through standard valuation tools before finishing with a broader way to think about what the stock is really worth.

Stryker scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Stryker Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting those back to today using a required return. It focuses on cash the company can generate for shareholders rather than just reported earnings.

For Stryker, the model uses last twelve months Free Cash Flow of about $4.6b as a starting point. Analysts provide explicit forecasts for several years, and Simply Wall St then extends those estimates out to 10 years using its own extrapolations. By 2035, Free Cash Flow is projected at around $8.5b, with each year between 2026 and 2035 discounted back to today under a 2 Stage Free Cash Flow to Equity framework.

Aggregating these discounted cash flows results in an estimated intrinsic value of about $367.59 per share. Compared with the recent share price of about $306.76, the DCF output suggests Stryker trades at roughly a 16.5% discount. On this measure, the stock appears undervalued relative to the model’s estimate of intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 16.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Stryker Price vs Earnings

P/E is a common way to value profitable companies because it links what you pay for the stock to the earnings each share generates. In general, higher expected growth and lower perceived risk can justify a higher P/E, while lower growth expectations or higher risk usually call for a lower, more cautious multiple.

Stryker currently trades on a P/E of about 35.24x. That is above the Medical Equipment industry average of about 25.17x and also higher than the peer group average of about 29.19x. On those simple comparisons, the stock looks relatively expensive.

Simply Wall St’s Fair Ratio for Stryker is 31.22x. This is a proprietary estimate of what a reasonable P/E could be, given factors such as earnings growth profile, profit margins, industry, market cap and company specific risks. Because it adjusts for these characteristics, the Fair Ratio can be more useful than a broad peer or industry comparison, which treats very different companies as if they were the same.

With the current P/E of 35.24x sitting above the Fair Ratio of 31.22x, the multiple based view points to the stock trading at a premium.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Stryker Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St’s Community page that lets you set out your own story for Stryker by choosing assumptions for revenue, earnings and margins. You can then link that story to a forecast and to a fair value that you can compare with the current price to help decide whether to buy, hold or sell. The model automatically updates when fresh news or earnings arrive. One investor might build a cautious Stryker Narrative around a fair value near US$323.52, while another uses more optimistic assumptions and arrives closer to US$389.35. Both can clearly see how their different views translate into different fair values.

Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.